Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P08590
UPID:
MYL3_HUMAN
Alternative names:
Cardiac myosin light chain 1; Myosin light chain 1, slow-twitch muscle B/ventricular isoform; Ventricular myosin alkali light chain; Ventricular myosin light chain 1; Ventricular/slow twitch myosin alkali light chain
Alternative UPACC:
P08590; B2R534; Q9NRS8
Background:
Myosin light chain 3, also known as cardiac myosin light chain 1, plays a crucial role as a regulatory light chain of myosin. It is pivotal in heart muscle function, not binding calcium, and is expressed in various isoforms including ventricular and slow-twitch muscle B/ventricular isoform. This protein's intricate involvement in muscle contraction mechanics underscores its importance in cardiac physiology.
Therapeutic significance:
Cardiomyopathy, familial hypertrophic, 8, a severe hereditary heart disorder, is directly linked to mutations affecting Myosin light chain 3. Characterized by ventricular hypertrophy, this condition can lead to sudden cardiac death. Understanding the role of Myosin light chain 3 could pave the way for innovative therapeutic strategies targeting the molecular basis of heart diseases.